Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Qingre granules versus buspirone for generalized anxiety disorder
ChiCTR-IPR-17013058Phase 4Not yet recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Shugan Qingre granules arm with Buspirone control arm (2 arms). Primary endpoint: Hamilton Anxiety Rating Scale. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
Shugan Qingre granulesbuspirone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on ChiCTR-IPR-17013058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013058.